HC Wainwright Begins Coverage on Envoy Medical (NASDAQ:COCH)

Equities researchers at HC Wainwright assumed coverage on shares of Envoy Medical (NASDAQ:COCH) in a research note issued on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $2.50 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 288.86% from the stock’s current price.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Envoy Medical in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.00.

Envoy Medical Trading Down 1.5%

Shares of COCH stock opened at $0.64 on Tuesday. The stock has a 50 day moving average of $0.68 and a two-hundred day moving average of $0.77. Envoy Medical has a 12 month low of $0.36 and a 12 month high of $1.91. The company has a market capitalization of $49.43 million, a P/E ratio of -0.53 and a beta of 2.08.

Envoy Medical (NASDAQ:COCH) last issued its earnings results on Monday, March 23rd. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.03 million. Sell-side analysts predict that Envoy Medical will post -1.21 earnings per share for the current fiscal year.

Insider Transactions at Envoy Medical

In other Envoy Medical news, Director Mona Chetan Patel acquired 312,500 shares of the business’s stock in a transaction on Thursday, February 12th. The stock was purchased at an average price of $0.40 per share, for a total transaction of $125,000.00. Following the transaction, the director owned 332,500 shares in the company, valued at $133,000. This trade represents a 1,562.50% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert Potashnick acquired 212,500 shares of Envoy Medical stock in a transaction on Thursday, February 12th. The stock was acquired at an average cost of $0.40 per share, for a total transaction of $85,000.00. Following the purchase, the chief financial officer owned 212,500 shares of the company’s stock, valued at approximately $85,000. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have purchased 20,433,650 shares of company stock worth $8,173,460. 5.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Envoy Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CIBC Bancorp USA Inc. acquired a new position in shares of Envoy Medical during the third quarter worth approximately $60,000. Geode Capital Management LLC lifted its holdings in Envoy Medical by 111.3% during the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock worth $65,000 after buying an additional 51,813 shares in the last quarter. Finally, Focus Partners Wealth bought a new position in Envoy Medical in the 1st quarter valued at $276,000. Institutional investors and hedge funds own 8.59% of the company’s stock.

Envoy Medical Company Profile

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.